Thetis Pharmaceuticals LLC
Thetis is pioneering the development of novel lipid-based drugs for GI diseases with high unmet medical needs. Using our proprietary HEALER™ chemistry platform, we transform bioactive lipids into NMEs with improved pharmaceutical properties and strong IP protection. We focus on indications in which the bioactive lipid delivered by our HEALER technology has established safety and efficacy data. Our lead candidate, TP-252, is targeted at two indications: ulcerative colitis and FAP (a rare genetic disease). We hope to enter the clinic in 2018.
Beyond TP-252, we are pursuing an exploratory program in IBD with a new class of bioactive lipids known as Specialized Proresolving Mediators (SPMs).
DDW Tracks Microbiome in Gastrointestinal and Liver Diseases, Inflammatory Bowel Diseases, Liver Diseases and Transplantation, Esophageal Diseases, Stomach and Small Bowel Disorders, Colorectal Diseases, Functional GI and Motility Disorders, Pancreatic Diseases, Biliary Tract Diseases
Does your company only service US attendees? No
Is your company a new exhibiting company? Yes